MAM
TIL icon

Martingale Asset Management’s Instil Bio TIL Stock Holding History

Martingale Asset Management’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-945
Closed -$92K – 888
2022
Q3 		$92K Buy
945
+308
+48% +$35.2K ﹤0.01% 809
2022
Q2 		$59K Buy
+637
New +$90.2K ﹤0.01% 834

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's TIL Position: Q4 2022 in Review

Martingale Asset Management sold out of Instil Bio (TIL) in Q4 2022, closing a stake of 945 shares — an estimated $92K sold.

Martingale Asset Management first reported a position in TIL in Q2 2022 and held it in 2 quarters. The position peaked at $92K in Q3 2022. 78 funds tracked by Wall St. Rank hold TIL as of Q4 2022.

  • Martingale Asset Management reported no remaining Instil Bio position as of Q4 2022 after selling out during the quarter.
  • Martingale Asset Management sold 945 Instil Bio shares in Q4 2022, an estimated $92K.
  • Martingale Asset Management first reported a position in Instil Bio in Q2 2022 and held it in 2 quarters.
  • Martingale Asset Management's Instil Bio position peaked at $92K in Q3 2022.
  • 78 funds tracked by Wall St. Rank held Instil Bio as of Q4 2022.

Based on Martingale Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.